Immatics N.V.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 1.56M | $15.37M | 0.00% | Trimmed-4.5% | 2026-03-31 |
| Citadel | multi-strat | 1.49M | $14.70M | 0.02% | Trimmed-14.8% | 2026-03-31 |
| StateStreet | passive | 457.0K | $4.50M | 0.00% | Added+2.8% | 2026-03-31 |
| FidelityFMR | fundamental | 2.2K | $21.96K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 652.2K | $6.42K | 0.00% | Trimmed-12.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.48 | — | — |
| 2026-05-12 | -0.44 | -0.51 | -15.53% |
| 2026-03-05 | -0.48 | -0.34 | +29.17% |
| 2025-11-17 | -0.45 | -0.49 | -7.38% |
| 2025-08-13 | -0.36 | -0.68 | -88.34% |
| 2025-05-13 | -0.33 | -0.37 | -10.36% |
| 2025-03-27 | -0.34 | 0.45 | +234.26% |
| 2024-11-18 | -0.28 | -0.08 | +69.36% |
| 2024-08-13 | -0.31 | -0.19 | +39.17% |
| 2024-05-14 | -0.22 | -0.03 | +85.28% |
| 2024-03-21 | -0.39 | -0.33 | +17.04% |
| 2023-11-14 | -0.39 | -0.34 | +11.62% |
| 2023-08-17 | -0.27 | -0.35 | -28.49% |
| 2023-05-16 | -0.30 | -0.28 | +5.62% |
| 2023-03-21 | -0.08 | -0.25 | -212.09% |
| 2022-11-17 | -0.44 | -0.33 | +24.14% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IMTX | +6.67% | +16.97% | +9.62% | +113.54% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.70% | +21.61% | +13.06% | +100.86% |